Janney Montgomery Scott LLC increased its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 90.1% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 24,636 shares of the company’s stock after buying an additional 11,679 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Ventyx Biosciences were worth $808,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of VTYX. Bank of New York Mellon Corp increased its holdings in Ventyx Biosciences by 38.1% in the 1st quarter. Bank of New York Mellon Corp now owns 24,242 shares of the company’s stock worth $329,000 after buying an additional 6,688 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Ventyx Biosciences by 3.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 73,803 shares of the company’s stock worth $1,002,000 after buying an additional 2,482 shares in the last quarter. State Street Corp increased its holdings in Ventyx Biosciences by 65.2% in the 1st quarter. State Street Corp now owns 171,195 shares of the company’s stock worth $2,323,000 after buying an additional 67,590 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Ventyx Biosciences by 57.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 11,984 shares of the company’s stock worth $147,000 after buying an additional 4,391 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Ventyx Biosciences in the 2nd quarter worth about $311,000.
Ventyx Biosciences Stock Down 4.3 %
VTYX stock opened at $15.11 on Friday. Ventyx Biosciences, Inc. has a twelve month low of $15.03 and a twelve month high of $47.25. The stock has a market cap of $887.11 million, a P/E ratio of -5.40 and a beta of -0.34. The business’s 50-day moving average price is $29.19 and its 200-day moving average price is $32.95.
Insider Activity at Ventyx Biosciences
In related news, Director Somu Subramaniam sold 10,803 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $37.59, for a total transaction of $406,084.77. Following the sale, the director now owns 8,545,452 shares of the company’s stock, valued at approximately $321,223,540.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ventyx Biosciences news, insider William J. Sandborn sold 11,900 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $37.16, for a total value of $442,204.00. Following the sale, the insider now owns 48,389 shares of the company’s stock, valued at approximately $1,798,135.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Somu Subramaniam sold 10,803 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $37.59, for a total value of $406,084.77. Following the completion of the sale, the director now directly owns 8,545,452 shares in the company, valued at approximately $321,223,540.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 228,914 shares of company stock valued at $7,666,556. 24.39% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Several research firms recently commented on VTYX. Stifel Nicolaus reiterated a “buy” rating and issued a $56.00 price objective on shares of Ventyx Biosciences in a report on Tuesday, October 10th. Credit Suisse Group dropped their target price on Ventyx Biosciences from $63.00 to $62.00 and set an “outperform” rating on the stock in a research report on Friday, August 11th. Oppenheimer dropped their target price on Ventyx Biosciences from $57.00 to $56.00 in a research report on Tuesday, October 10th. HC Wainwright reissued a “buy” rating and issued a $52.00 target price on shares of Ventyx Biosciences in a research report on Tuesday, October 10th. Finally, Evercore ISI dropped their target price on Ventyx Biosciences from $65.00 to $47.00 in a research report on Tuesday, October 10th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $55.56.
Get Our Latest Analysis on VTYX
Ventyx Biosciences Profile
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Articles
- Five stocks we like better than Ventyx Biosciences
- What Are Dividend Challengers?
- Watch for bears as S&P 500 slices 200-day line
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Reasons UPS is a strong sell: Reasons to buy it when it bottoms
- Canada Bond Market Holiday: How to Invest and Trade
- 3 hot mid-caps set to report Q3 earnings
Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report).
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
